secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-022193
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q1 2023 net loss $70.8M; four Phase 3 readouts expected in Q3 2023
--------------------------------------------------------------------------------

- Cash position $421.2M; net loss $70.8M ($1.35/share) vs $95.7M ($1.83/share) Q1 2022.
- R&D expenses $56.5M (down from $76.2M) due to maturation of tarcocimab program and manufacturing timing.
- Topline data for GLEAM, GLIMMER, DAYLIGHT studies expected July 2023; GLOW study expected September 2023.
- BEACON Phase 3 study met primary endpoint in 2022; company plans single BLA for tarcocimab if successful.
- Phase 1 dosing started for KSI-501 bispecific antibody biopolymer conjugate in DME.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023022193/0000950170-23-022193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023022193/kod-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer